The cellular origin of chronic lymphocytic leukemia (CLL) is still debated, although this information is critical to understanding its pathogenesis. Transcriptome analyses of CLL and the main normal B cell subsets from human blood and spleen revealed that immunoglobulin variable region (IgV) gene unmutated CLL derives from unmutated mature CD5(+) B cells and mutated CLL derives from a distinct,...

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell chronic lymphocytic leukemia (B-CLL). Here, we show that post-alloHSCT antibody repertoires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cell-surface antigens. Sera collected from B-CLL patients at defined times after alloHSC...

Chronic lymphocytic leukemia (CLL) is the most common apoptosis, CLL B-cell proliferation was variably inhibited leukemia of the western world and is characterized by a with addition of TGF-b. In vitro addition of IL-4, previously slowly progressing accumulation of clonal CD5 B cells. Our reported to promote CLL B-cell survival, dramatically relaboratory has investigated the role of transformin...

OBJECTIVES B-lymphoblastic leukemia (B-LBL) arising in patients with chronic lymphocytic leukemia (CLL) is exceedingly rare and poorly characterized. METHODS We describe four patients with CLL and concurrent or subsequent B-LBL diagnosed by morphologic, immunophenotypic, cytogenetic, and molecular analysis and reviewed the literature. RESULTS In three patients, B-LBL followed CLL by 5 to 15...

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only potentially curative treatment available for patients with B-cell chronic lymphocytic leukemia (B-CLL). Here, we show that post-alloHSCT antibody repertoires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cellsurface antigens. Sera collected from B-CLL patients at defined times after alloHSCT...

B chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of slow-dividing and long-lived monoclonal B cells arrested at the intermediate stage of their differentiation. We previously showed that interleukin 4 (IL-4) not only inhibits but also prevents the proliferation of B-CLL cells. We report here that IL-4 protects the B-CLL cells from death by apoptosis (programmed cell d...

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Despite aggressive treatment regimen B-Cell Chronic Lymphocytic Leukemia (CLL) is still incurable. Previously we defined the role of a novel receptor tyrosine kinase (RTK) Axl in CLL B-cell survival. In this study we demonstrated the impact of Axl inhibition on CLL B-cell survival using a high-...

Abstract Stereotyped B-cell receptors (BCR) are frequent in patients with chronic lymphocytic leukemia (CLL). In cell culture and mouse models of CLL, immunogenic epitopes these BCRs were shown to trigger specific T-cell responses control development. These results suggest vaccination autologous BCR-derived peptides as a novel therapy for CLL. See related article by Rovida et al., p. 729

B chronic lymphocytic leukemia (B-CLL) are clonal populations of mIgM+ or mIgM+/mIgD+ CD5+ B cells that appear to be arrested in the follicular mantle-zone B-cell stage. Functional analyses have shown two groups of B-CLL that can be distinguished based on their capacity to proliferate in response to B-cell antigen receptor complex (BCR) cross-linking. To investigate the molecular basis for this...

Although B-cell chronic lymphocytic leukemia (B-CLL) clones with unmutated IGHV genes (U-CLL) exhibit greater telomerase activity than those with mutated IGHV genes (M-CLL), the extent to which B-cell receptor (BCR) triggering contributes to telomerase up-regulation is not known. Therefore, we studied the effect of BCR stimulation on modulating telomerase activity. The multivalent BCR ligand, d...